Allen and colleagues explored the effects of anti-PD-L1 (B20S) therapy in combination with anti-VEGFR2 (DC101) in mice bearing mammary carcinoma, glioblastoma and pancreatic neuroendocrine tumor. This evidence concerns the gene CD274 and breast carcinoma.